Next Article in Journal
Secondary Structural Model of MALAT1 Becomes Unstructured in Chronic Myeloid Leukemia and Undergoes Structural Rearrangement in Cervical Cancer
Previous Article in Journal
Exosomes in Immune Regulation
Open AccessArticle

Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma

1
Department of Dermatology, University Hospital of Zürich, Gloriastrasse 31, 8091 Zürich, Switzerland
2
Faculty of Medicine, University of Zürich, 8091 Zürich, Switzerland
3
Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari “A. Moro”, 70121 Bari, Italy
4
Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies (IBIOM), National Research Council, 70126 Bari, Italy
5
Department of Dermatology and Allergy, University Hospital, LMU Munich, 80336 Munich, Germany
6
Department of Dermatology, Lausanne University Hospital and Faculty of Biology and Medicine, University of Lausanne, 1015 Lausanne, Switzerland
*
Author to whom correspondence should be addressed.
Non-Coding RNA 2021, 7(1), 5; https://doi.org/10.3390/ncrna7010005
Received: 18 September 2020 / Revised: 5 January 2021 / Accepted: 8 January 2021 / Published: 12 January 2021
(This article belongs to the Special Issue Research on RNA Modification)
Background: RNA editing is a highly conserved posttranscriptional mechanism that contributes to transcriptome diversity. In mammals, it includes nucleobase deaminations that convert cytidine (C) into uridine (U) and adenosine (A) into inosine (I). Evidence from cancer studies indicates that RNA-editing enzymes promote certain mechanisms of tumorigenesis. On the other hand, recoding editing in mRNA can generate mutations in proteins that can participate in the Major Histocompatibility Complex (MHC) ligandome and can therefore be recognized by the adaptive immune system. Anti-cancer treatment based on the administration of immune checkpoint inhibitors enhance these natural anti-cancer immune responses. Results: Based on RNA-Seq datasets, we evaluated the editome of melanoma cell lines generated from patients pre- and post-immunotherapy with immune checkpoint inhibitors. Our results reveal a differential editing in Arthrobacter luteus (Alu) sequences between samples pre-therapy and relapses during therapy with immune checkpoint inhibitors. Conclusion: These data pave the way towards the development of new diagnostics and therapies targeted to editing that could help in preventing relapses during immunotherapies. View Full-Text
Keywords: editing; melanoma; ADAR; Alu sequences; immune checkpoint inhibitors; immunotherapy editing; melanoma; ADAR; Alu sequences; immune checkpoint inhibitors; immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

Tusup, M.; Cheng, P.F.; Picardi, E.; Raziunaite, A.; Dummer, R.; Levesque, M.P.; French, L.E.; Guenova, E.; Kundig, T.M.; Pascolo, S. Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma. Non-Coding RNA 2021, 7, 5. https://doi.org/10.3390/ncrna7010005

AMA Style

Tusup M, Cheng PF, Picardi E, Raziunaite A, Dummer R, Levesque MP, French LE, Guenova E, Kundig TM, Pascolo S. Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma. Non-Coding RNA. 2021; 7(1):5. https://doi.org/10.3390/ncrna7010005

Chicago/Turabian Style

Tusup, Marina; Cheng, Phil F.; Picardi, Ernesto; Raziunaite, Austeja; Dummer, Reinhard; Levesque, Mitchell P.; French, Lars E.; Guenova, Emmanuella; Kundig, Thomas M.; Pascolo, Steve. 2021. "Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma" Non-Coding RNA 7, no. 1: 5. https://doi.org/10.3390/ncrna7010005

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop